Background: Interferons (IFNs) are cytokines involved in the immune response with a synergistic regulatory effect on the immune response. They are therapeutics for various viral and proliferative conditions, with proven safety and efficacy. Their clinical application is challenging due to the molecules' size, degradation, and pharmacokinetics. We are working on new drug delivery systems that provide adequate therapeutic concentrations for these cytokines and prolong their half-life in the circulation, such as nanoformulations. Methods: Through nanoencapsulation using electrospray technology and biocompatible and biodegradable polymers, we are developing a controlled release system based on nanoparticles for viral infections of the respiratory tract. Results: We developed a controlled release system for viral respiratory tract infections. A prototype nanoparticle with a core was created, which hydrolyzed the polyvinylpyrrolidone (PVP) shell , releasing the active ingredients interferon-alpha (IFN-α) and interferon-gamma (IFN-γ). The chitosan (QS) core degraded slowly, with a controlled release of IFN-α. The primary and rapid effect of the interferon combination ensured an antiviral and immunoregulatory response from day one, induced by IFN-α and enhanced by IFN-γ. The multilayer design demonstrated an optimal toxicity profile. Conclusions: This formulation is an inhaled dry powder intended for the non-invasive intranasal route. The product does not require a cold chain and has the potential for self-administration in the face of emerging viral infections. This novel drug has applications in multiple infectious, oncological, and autoimmune conditions, and further development is proposed for its therapeutic potential. This prototype would ensure greater bioavailability, controlled release, fewer adverse effects, and robust biological action through the simultaneous action of both molecules.
Multilayer Nanocarrier for the Codelivery of Interferons: A Promising Strategy for Biocompatible and Long-Acting Antiviral Treatment.
用于共递送干扰素的多层纳米载体:一种有前景的生物相容性和长效抗病毒治疗策略
阅读:6
作者:Ramos Thelvia I, Villacis-Aguirre Carlos A, Sandoval Felipe Sandoval, Martin-Solano Sarah, Manrique-Suárez Viana, RodrÃguez Hortensia, Santiago-Padilla Leandro, Debut Alexis, Gómez-Gaete Carolina, Arias Marbel Torres, Montesino Raquel, Lamazares Emilio, Cabezas Ignacio, Hugues Florence, Parra Natalie C, Altamirano Claudia, Ramos Oliberto Sánchez, Santiago-Vispo Nelson, Toledo Jorge R
| 期刊: | Pharmaceutics | 影响因子: | 5.500 |
| 时间: | 2024 | 起止号: | 2024 Oct 22; 16(11):1349 |
| doi: | 10.3390/pharmaceutics16111349 | 种属: | Viral |
| 研究方向: | 其它 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
